ZVRA — Zevra Therapeutics Inc
NASDAQ · Pharmaceuticals · Pharmaceuticals
- Latest Close
- $9.81
- 30-Day Move
- +20.8%
- Market Cap
- $586M
- Shares Outstanding
- 58,710,000
- P/E Ratio
- 6.65
- P/B Ratio
- 3.26
Zevra Therapeutics Inc
A read-only Alphactor snapshot forZevra Therapeutics Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-27
Topline snapshot
Latest Close
$9.81
30-Day Move
+20.8%
Market Cap
$586M
Shares Outstanding
58,710,000
P/E Ratio
6.65
P/B Ratio
3.26
$9.81
+20.8%last 90 delayed daily bars
90D High
$11.40
90D Low
$8.01
Avg Volume
1,004,863
Gross margin is running at 96.4%, which gives a quick read on operating quality before you open the full model.
Net margin is 78.2%, useful for comparing ZVRA against peers in Pharmaceuticals.
ZVRA is up 20.8% over the last 30 trading days shown on this page.
Latest operating income is $-4M, which helps anchor the headline ratios with an actual earnings figure.
Composite Fair Value
$9.05
Rule of 40
348.6%
Latest Close
$9.81
30-Day Move
+20.8%
Market Cap
$586M
Shares Outstanding
58,710,000
P/E Ratio
6.65
P/B Ratio
3.26
ROE
53.8%
ROA
29.2%
Gross Margin
96.4%
Operating Margin
-59.1%
Net Margin
78.2%
Debt / Equity
0.4
Current Ratio
5.68
Latest Revenue
$106M
Revenue
$106M
Gross Profit
$90M
Operating Income
$-4M
Net Income
$83M
Gross Margin
9637.0%
Net Margin
7817.0%
Current Ratio
5.68
Debt / Equity
0.40
Fair Value
$9.05
Upside / Downside
-7.7%
Signal
Fairly Valued
Implied Growth
--
EV/Rev
$9.05
Growth Assumption
50.0%
Discount Rate
9.6%
Terminal Growth
2.0%
Base FCF
--
Valuation spread
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Negative FCF — company is cash-flow negative. Reverse DCF requires positive cash flows.
Altman Z
1.73
Distress
Piotroski
6
Moderate (4-6)
Cash Conversion
-0.02x
Rule of 40
348.6%
Elite
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $10M | $-25M | $-27M | $-19M |
| 2023-12-31 | $27M | $-50M | $-46M | $-34M |
| 2024-12-31 | $24M | $-87M | $-106M | $-70M |
| 2025-12-31 | $106M | $-4M | $83M | $-2M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
BlackRock
Filed 2024-05-10
$14M
--
Marshall Wace
Filed 2025-11-13
$9M
--
Citadel Advisors
Filed 2026-02-17
$8M
--
Man Group
Filed 2026-02-17
$827,429
+174.4%
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.